Also considered
11 papers judged, 1 emailed · Read the digest →
Phase 3 RCT (MATTERHORN) in resectable gastric/GEJ adenocarcinoma testing perioperative durvalumab added to FLOT chemotherapy, published in Lancet, now reporting final overall survival results. Findings support or refute durvalumab plus FLOT as a new perioperative standard of care.
Expert description in JNCI (elite) of the updated WHO classification introducing new gastric neuroendocrine tumor subtypes (types 4 and 5), driven by parietal cell dysfunction or PPI use. Clarifies diagnostic categorization to avoid unnecessary radical surgery, directly informing pathology-guided management decisions.
Multicenter translational study developing a deep-learning CT model to noninvasively predict tumor tertiary lymphoid structures in pancreatic cancer, published in J Immunother Cancer. Predicted TLS status was associated with survival and validated in a prospective immunochemotherapy cohort, suggesting potential to noninvasively select patients likely to benefit from immunotherapy.
Translational study in Journal for ImmunoTherapy of Cancer using single-cell and clinical gastric cancer cohorts to identify PRKX-driven PD-L1 stabilization as a marker of an immunosuppressive tumor subtype. High PRKX/PD-L1 tumor cell density predicted poor survival in anti-PD-1-treated patients, suggesting a potential biomarker to guide immunotherapy selection in gastric cancer.
Preclinical translational study (J Immunother Cancer) combining epigenetic and cytokine therapy with anti-PD-1 in checkpoint-resistant murine colorectal and breast cancer models, identifying an immune-niche gene signature associated with favorable clinical response to checkpoint blockade in patient genomic datasets. Suggests a rational combination strategy and biomarker to overcome anti-PD-1 resistance, though still early-stage evidence.
Single-arm phase 2 study of camrelizumab plus nimotuzumab as second-line therapy in advanced esophageal squamous cell carcinoma, published in Journal for ImmunoTherapy of Cancer. Shows modest response and survival benefit including in immunotherapy-pretreated patients, supporting further study of this combination but not yet practice-changing.
Translational study in Clinical Cancer Research assessing expression, heterogeneity, and genomic correlates of five antibody-drug conjugate targets (CLDN18.2, c-MET, Nectin-4, TROP2, HER2) in resected biliary tract cancer specimens. Provides target-expression landscape data to inform future ADC trial design but does not yet link expression to treatment response.
Case report with accompanying narrative literature review in J Gastrointest Oncol on neuroendocrine tumors of unknown primary with gastroenteropancreatic features. Summarizes diagnostic and therapeutic approaches (e.g., somatostatin analogs) for this uncommon entity but is not practice-changing.
Preclinical study in Clinical Cancer Research evaluating GPC3-targeted PET imaging and alpha-particle radiotherapy in orthotopic hepatocellular carcinoma mouse models, showing tumor control and survival benefit. Promising theranostic concept but confined to animal models with no patient data yet.
Single-arm phase 2 trial in RAS/BRAF wild-type metastatic colorectal cancer patients previously benefiting from cetuximab, published in Clinical and Translational Medicine. Uses ctDNA testing to select patients for cetuximab/irinotecan rechallenge, showing modest activity that could inform sequencing decisions after anti-EGFR resistance.
Small retrospective multicenter study in FGFR2-rearranged intrahepatic cholangiocarcinoma examining futibatinib activity after progression on non-covalent FGFR inhibitors, published in European Journal of Cancer. Provides real-world guidance on FGFR inhibitor sequencing and resistance mutation patterns to inform later-line treatment choices.